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Supplementary Figure 1 | Quantile-quantile plots of NTS association in Kenyan discovery samples. Under 
(a) additive (5,585,198 SNPs, λ = 1.01) and (b) genotypic (4,669,480 SNPs, λ = 1.01) models. Observed -
log10(P-values)/test statistics are plotted against those expected under a χ2 distribution with 1 degree of freedom 
(additive model) and two degrees of freedom (genotypic model). For reference, genome-wide inflation factors 
under recessive dominant and heterozygous advantage models of association are 1.02, 1.00, and 1.00 
respectively. 
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Supplementary Figure 2 | Principal components of Kenyan discovery genome-wide genotyping data. 
Individuals are color-coded according to (a) self-reported ethnicity and (b) case-control status. The first four 
principal components are displayed.  
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Supplementary Figure 3 | Manhattan plots of NTS association in Kenyan discovery samples. Under (a) 
additive (5,585,198 SNPs) and (b) genotypic (4,669,480 SNPs) models of association. The upper (red) 
horizontal line denotes genome-wide significance (P=5x10-8), the lower (blue) horizontal denotes suggestive 
association (P=1x10-6) used as the threshold for replication. 
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Supplementary Figure 4 | rs13390936 association with NTS bacteraemia in Kenyan children with and 
without acquired risk factors for NTS. Log-transformed odds ratios and 95% confidence intervals of 
rs13390936 association (recessive model) with NTS bacteraemia in Kenyan discovery samples (left panels), 
stratified by (a) malaria co-infection, (b) malnutrition (severe wasting*), and (c) HIV co-infection among cases. 
Posterior probabilities of models of association at rs13390936 (right panels): NULL, no association with any 
NTS serovar; NTS – no malaria/malnutrion, a non-zero effect in NTS bacteraemia without malaria/malnutrion 
alone; NTS – with malaria/malnutrion, a non-zero effect in NTS bacteraemia with malaria/malnutrion alone; 
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BOTH, the same non-zero effect in both children with and without acquired risk factors. The models in which 
NTS bacteraemia in children with and without malaria and malnutrition (highlighted in red) is associated with 
rs13390936 with the same effect size are the most probable (Bayes factor c.f. NULL = 3,784 and 13,583 
respectively). The number of HIV-infected children with NTS bacteraemia (n=24) in the Kenyan discovery 
samples is too small to permit a stratified analysis. 
 
*Severe wasting defined as weight-for-age z-scores <-3. 
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Supplementary Figure 5 | Association at the sickle cell locus (rs334) with NTS bacteraemia in the Kenyan 
discovery samples (a). Genotype at rs334 (cases=164, HbAA=129, HbAS=26, HbSS=9; controls=2,342, 
HbAA=1,876, HbAS=437, HbSS=29) is not associated with risk of NTS bacteraemia in Kenyan children under 
an additive model (logistic regression, P=0.07; OR 1.35 95% CI 0.96-1.85). There is no statistically significant 
evidence for a protective effect of HbAS carriage (HbAS vs. HbAA) on risk of NTS bacteraemia in these 
children (logistic regression, P=0.65; OR 0.90 95% CI 0.57-1.38). Carriage of HbSS (HbSS vs. HbAA) is 
associated with increased risk of NTS bacteraemia (logistic regression, P=8.30x10-5; OR 4.89 95% CI 2.10-
10.40). Association at the STAT4 locus with NTS bacteraemia is independent of genotype at the sickle cell 
locus (b). NTS-association at the STAT4 region under the recessive model not conditioned on genotype (top 
panel) in Kenyan discovery samples (n=180 cases, 2,677 controls). rs13390936 is highlighted in blue. SNPs are 
coloured according to strength of linkage disequilibrium (r2) to rs13390936. SNPs in a credible SNP set, which 
includes the causal variant with >95% probability, are ringed with black circles. NTS association at the STAT4 
region is conditioned on genotype at rs334 under a heterozygote advantage model (HbAS carriage – middle 
panel) and under a recessive model (HbSS carriage – bottom panel).  
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Supplementary Figure 6 | Linkage disequilibrium at the STAT4 locus in Kenyan and European study 
subjects. NTS association under a recessive model at the STAT4 locus (top) in Kenyan discovery samples (n = 
180 cases, 2,677 controls). SNPs are colored according to strength of linkage disequilibrium (LD; r2) to 
rs13390936 (in blue). SNPs in a credible SNP set, which includes the causal variant with >95% probability, are 
ringed with black circles. The plot is annotated with standardized varLD scores (purple line), quantifying the 
evidence for differential linkage disequilibrium between Kenyan discovery samples and European samples used 
in the eQTL analyses (n=421). The dashed purple line indicates regions with no evidence for differential LD 
between the two populations, the solid purple line indicates evidence of differential LD (varLD score >95th 
centile). LD plots (Haploview v4.2) of the STAT4 region in the Kenyan (middle) and European (bottom) 
samples, have the haplotype containing rs13390936 highlighted with a blue triangle. Red squares indicate 
strong evidence of pairwise LD (D’=1, LOD score – log odds of data likelihood under LD vs linkage 
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equilibrium - >2); pink squares indicate LOD>2, D’<1; blue squares, D’=1, LOD<2; white squares, D’<1, 
LOD<2. 
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Supplementary Figure 7 | Effect of rs13390936 genotype on IFNγ production in CD4+ T cells. (a) Gating 
strategy for IFNγ+ CD4+ T cells. Representative IFNγ production in naïve, IL-12- and NTS-stimulated CD4+ T 
cells. (b) The proportion of IFNγ+ CD4+ T cells is not modified by rs13390936 genotype in naïve (meanAA = 
0.017%, meanTT = 0.016%, Wilcoxon rank-sum P = 0.941), IL-12 stimulated (meanAA = 0.017%, meanTT = 
0.015%, Wilcoxon rank-sum P = 0.727) or NTS-stimulated (meanAA = 0.062%, meanTT = 0.055%, Wilcoxon 
rank-sum P = 0.132) cells in 54 (protective AA genotype, n = 36; susceptible TT genotype, n = 18) healthy 
European adults. ns, not significant. 
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Supplementary Figure 8 | IFNγ production in HIV-infected and HIV-uninfected Malawian children with 
NTS bacteraemia. (a) HIV-uninfected Malawian children (total n=61; rs13390936:AA, n=44; TA, n=14; TT, 
n=3) with the NTS-susceptibility (T) allele have reduced circulating levels of IFNγ during acute NTS 
bacteraemia (meanAA = 650.3pg/ml, meanTT = 292.6pg/ml), in a linear model adjusted for age, sex, malaria and 
malnutrition. (b) HIV-infected Malawian children (total n=43; rs13390936:AA, n=32; TA, n=10; TT, n=1) with 
the NTS-susceptibility (T) allele do not have statistically significantly reduced circulating levels of IFNγ during 
acute NTS bacteraemia (meanAA = 568.9pg/ml, meanTT = 247.7pg/ml), in a linear model adjusted for age, sex, 
malaria and malnutrition. P-values are calculated by linear regression and ANOVA. 
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Supplementary Figure 9 | (a) rs13390936 association with major NTS serovars in Kenyan children. Log-
transformed odds ratios and 95% confidence intervals of rs13390936 association (recessive model) in Kenyan 
discovery samples. (b) Posterior probabilities of models of association at rs13390936: NULL, no association 
with any NTS serovar; SEN, a non-zero effect in S. Enteritidis bacteraemia alone; STM, a non-zero effect in S. 
Typhimurium bacteraemia alone; BOTH, the same non-zero effect in both NTS serovars. In a comparison of all 
possible combinations of rs13390936 association with NTS serovars, the model in which bacteraemia secondary 
to both S. Typhimurium and S. Enteritidis (highlighted in red) is associated with rs13390936 is the most 
probable (Bayes factor c.f. NULL = 225). 
  
 
 
 
 
12 
 
 
Supplementary Figure 10 | Statistical power in replication experiments. Statistical power to detect an 
association (P<0.05) of varying effect size in (a) Kenyan replication samples (38 cases, 1,336 controls) and (b) 
Malawian replication samples (150 cases, 339 controls) given different minor allele frequencies (MAF). 
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Supplementary Figure 11 | HRMA genotyping of rs13390936. Representative normalized melting curves 
(top) and peaks (bottom) from rs13390936 HRMA genotyping. Data is taken from a single assay (96 
individuals). Genotypes are color-coded as follows; AA, grey, AT red, TT blue. 
  
 
 
 
 
14 
 
 
 
Supplementary Figure 12 | Principal components of Kenyan replication genome-wide genotyping data. 
Individuals are color-coded according to (a) self-reported ethnicity and (b) case-control status. The first four 
principal components are displayed. 
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Kenyan discovery samples Kenyan replication samples 
  
Cases Controls Cases Controls 
 
Total before QC 218 3,000 49 1,444 
Ex
cl
us
io
n 
cr
ite
ria
 
Call rate & extreme heterozygosity 7 99 6 40 
HapMap PCA outliers 15 68 2 18 
Outlying channel intensity 0 12 1 1 
Sequenom discordance 0 13 0 8 
Discrepant or undetermined gender 4 14 1 2 
Duplicate samples 4 16 2 3 
Relatedness (IBD>0.4) 1 83 0 28 
Duplication of discovery samples in replication NA NA 1 12 
Genotyping failures 8 37 0 0 
 
Total after QC 180 2,677 38 1,336 
Supplementary Table 1 | Kenyan discovery & replication sample exclusions. Sample exclusions in the 
Affymetrix SNP 6.0 chip-genotyped Kenyan discovery and ImmunoChip-genotyped Kenyan replication sets. 
QC, quality control; IBD, Identity by descent. 
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Supplementary Table 2 | Kenyan discovery GWAS SNP exclusions. SNP exclusions in the Affymetrix SNP 
6.0 chip-genotyped Kenyan discovery samples, pre- and post-imputation. HWE, Hardy Weinberg Equilibrium. 
*While the imputation info threshold (0.8) is used in both additive and genotypic analyses, the metric is model 
specific, resulting in larger numbers of SNP exclusions in the genotypic analysis. 
 
Ge
no
ty
pe
d 
SN
P 
 
ex
cl
us
io
ns
 
Minor allele frequency <1% 50,322 
Info <0.975 53,419 
HWE P<1x10-20 18,288 
Plate effect P<1x10-6 7,382 
SNP missingness >2% 34,430 
 
Genotyped, autosomal SNPs taken 
forward for imputation 787,861 
    Additive model Genotypic model 
Im
pu
te
d 
SN
P 
ex
cl
us
io
ns
 HWE P<1x10
-10 1,684 
Minor allele frequency <10% 8,774,454 
Imputation info <0.8* 572,862 1,439,881 
 
Imputed, autosomal SNPs included 
in analysis 5,585,198 4,669,480 
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Supplementary Table 3 | Association between NTS bacteraemia and genotype at suggestively associated 
SNPs.  SNP (n = 67) suggestively associated with NTS bacteraemia (P<1x10-6) at 16 loci in Kenyan discovery 
SNP NTS association r2 to peak SNP in 
locus CHR BP (b37) RSID Freq. Info Score P Model 
1 29053720 rs4654369 0.264 0.969 7.88E-07 Genotypic 1.000 
1 29054752 rs10799120 0.264 0.971 7.85E-07 Genotypic 1 
1 194946012 rs866059 0.115 0.976 9.46E-07 Genotypic 1 
2 100773069 rs184422605 0.190 0.961 9.64E-07 Genotypic 0.770 
2 100789798 rs75776491 0.232 0.988 9.56E-07 Genotypic 0.978 
2 100795043 rs62150289 0.238 0.923 1.63E-08 Genotypic 1 
2 191954816 rs13390936 0.124 0.878 6.33E-07 Genotypic 1 
3 26761622 rs1488241 0.147 0.995 3.68E-07 Genotypic 0.780 
3 26768800 rs2171512 0.135 1.000 4.75E-07 Genotypic 0.730 
3 26768818 rs2129855 0.135 1.000 5.83E-07 Genotypic 0.727 
3 26769354 rs11713454 0.135 0.999 4.63E-07 Genotypic 0.730 
3 26769392 rs7430878 0.135 0.999 4.63E-07 Genotypic 0.730 
3 26769429 rs6790025 0.135 0.999 4.63E-07 Genotypic 0.730 
3 26771574 rs139655208 0.135 0.995 4.35E-07 Genotypic 0.730 
3 26792607 rs11914329 0.145 0.951 1.31E-08 Genotypic 0.803 
3 26792972 rs961399 0.145 0.951 1.31E-08 Genotypic 0.803 
3 26793518 rs1488248 0.145 0.953 1.39E-08 Genotypic 0.803 
3 26794821 rs1488250 0.136 1.000 5.28E-07 Genotypic 0.736 
3 26795026 rs1505577 0.145 1.000 6.04E-08 Genotypic 0.817 
3 26795765 rs1488251 0.135 0.999 3.00E-07 Genotypic 0.751 
3 26796445 rs6768401 0.134 1.000 2.00E-07 Genotypic 0.752 
3 26796598 rs1586506 0.134 0.999 2.00E-07 Genotypic 0.753 
3 26796765 rs1586507 0.134 0.999 1.96E-07 Genotypic 0.752 
3 26798069 rs1488254 0.143 0.985 1.70E-08 Genotypic 0.819 
3 26798614 rs1032885 0.142 0.979 1.25E-08 Genotypic 0.814 
3 26798992 rs4973809 0.142 0.978 1.20E-08 Genotypic 0.814 
3 26799072 rs6778280 0.143 0.978 1.35E-08 Genotypic 0.820 
3 26799395 rs1038636 0.143 0.977 1.33E-08 Genotypic 0.820 
3 26800829 rs6551141 0.157 0.848 2.12E-07 Genotypic 0.801 
3 26804954 rs10865806 0.158 0.932 3.85E-09 Genotypic 1 
4 83324569 rs11099533 0.111 0.858 6.86E-08 Genotypic 1 
4 88413965 rs17012693 0.214 0.920 2.06E-07 Additive 1 
4 88420287 rs2169502 0.222 0.923 3.95E-07 Additive 0.939 
7 35394619 rs138302119 0.115 0.848 4.47E-07 Genotypic 1 
8 73087935 rs1809447 0.113 0.825 6.61E-07 Genotypic 1.000 
8 73090061 rs13251057 0.113 0.822 6.49E-07 Genotypic 1 
8 134298504 rs16904882 0.112 0.954 1.08E-08 Additive 1 
8 139215025 rs11995943 0.184 0.836 5.20E-07 Genotypic  0.980 
8 139215155 rs11985359 0.184 0.831 5.05E-07 Genotypic  0.980 
8 139215247 rs13265099 0.184 0.826 4.60E-07 Genotypic  0.983 
8 139215574 rs4404965 0.189 0.806 1.85E-07 Genotypic 1 
8 139215649 rs7387858 0.188 0.806 2.23E-07 Genotypic  0.993 
10 121497290 rs73355807 0.154 0.915 6.40E-07 Genotypic 1 
12 125613150 rs78857905 0.123 0.832 2.89E-07 Additive 1 
12 125614614 rs76336213 0.118 0.806 6.65E-07 Additive 0.998 
12 125615610 rs75239828 0.118 0.805 6.44E-07 Additive 0.998 
12 125615627 rs75627386 0.122 0.804 3.26E-07 Additive 0.964 
13 69573095 rs73211763 0.112 0.830 2.99E-07 Genotypic 0.901 
13 69576658 rs73211791 0.112 0.836 2.56E-07 Genotypic 0.901 
13 69578250 rs73213609 0.112 0.832 2.10E-07 Genotypic 0.901 
13 69579168 rs55763812 0.126 0.999 1.45E-08 Genotypic 0.998 
13 69579594 rs73213613 0.124 1.000 7.10E-09 Genotypic 1.000 
13 69580147 rs1340723 0.112 0.827 1.80E-07 Genotypic 0.901 
13 69580255 rs9541701 0.124 1.000 7.05E-09 Genotypic 1.000 
13 69580286 rs9541702 0.124 1.000 7.04E-09 Genotypic 1.000 
13 69581350 rs7321066 0.112 0.824 1.65E-07 Genotypic 0.901 
13 69581690 rs9541704 0.124 1.000 6.99E-09 Genotypic 1.000 
13 69582697 rs12429197 0.111 0.811 1.87E-07 Genotypic 0.899 
13 69582740 rs9541709 0.124 0.955 3.78E-09 Genotypic 1 
19 7914568 rs550134 0.349 0.908 1.32E-07 Additive 1 
19 7915451 rs520802 0.440 0.847 6.52E-07 Genotypic 0.720 
19 7916475 rs2452012 0.349 0.908 1.34E-07 Additive 1.000 
19 7916620 rs580790 0.349 0.908 1.33E-07 Additive 1.000 
19 7922672 rs2059820 0.348 0.907 1.35E-07 Additive 1.000 
19 7932459 rs523648 0.432 0.834 7.70E-07 Genotypic 0.740 
21 35289246 rs2834301 0.158 1.000 8.59E-07 Genotypic 0.422 
21 35303773 rs8129054 0.275 0.805 1.25E-07 Genotypic 1 
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samples are displayed. CHR, chromosome; BP, base-pair position (Human Genome Reference GRCh37); 
RSID, SNP identifier; Freq, minor allele frequency.
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Supplementary Table 4 | Replication results and imputation accuracy of top SNPs (P<1x10-6) in NTS Kenyan discovery 
analysis. Genotype data was generated by imputation using the Affymetrix SNP 6.0 chip (Kenyan discovery samples) and Sequenom 
MASSArray (Kenyan replication and Malawian replication). Where ImmunoChip genotyping data was available (SNPs 
    
Kenyan discovery samples (180 cases; 2,677 controls) 
Kenyan replication samples (36 cases; 282 
controls) 
Malawian replication samples (135 cases; 
281 controls) 
Fixed effects meta-
analysis 
 
CHR BP (b37) SNP Gene 
MAF 
cases 
imputed 
MAF 
controls 
imputed 
Imputation 
accuracy P imputed 
OR (95% 
CI) 
imputed 
MAF 
cases  
MAF 
controls P OR (95% CI)  
MAF 
cases  
MAF 
controls P OR (95% CI)  P OR (95% CI) Model 
1 29053720 rs4654369   0.32 0.26 0.97 7.88x10-7   0.22 0.27 0.436   0.29 0.28 0.981       Genotypic 
1 194946012 rs866059   0.09 0.12 NA 9.46x10-7   NA NA NA   NA NA NA       Genotypic 
2 100795043 rs62150289 AFF3** 0.32 0.23 0.95 1.63x10-8   0.18 0.21 0.588   0.18 0.22 0.471       Genotypic 
2 191940260 rs16833239 STAT4** 0.17 0.13 0.95 1.80x10-5   0.13 0.11 2.51x10-3   0.15 0.13 0.080       Genotypic 
2 191954816 rs13390936 STAT4 0.17 0.12 0.97 6.33x10-7 
 
0.15 0.11 1.83x10-3 
 
0.15 0.14 0.039     
 
Genotypic 
2 191968420 rs13407419 STAT4** 0.17 0.13 0.97 1.18x10-5 
 
0.16 0.12 0.014 
 
NA NA NA     
 
Genotypic 
2 191970330 rs13401064 STAT4** 0.17 0.13 0.97 1.16x10-5  0.13 0.11 4.03x10-3  0.15 0.13 0.072      Genotypic 
3 26768818 rs2129855 LRRC3B* 0.17 0.13 NA 5.82x10-7   0.14 0.14 0.940   0.13 0.14 0.218       Genotypic 
3 26769354 rs11713454 LRRC3B 0.17 0.13 1.00 4.63x10-7   0.14 0.14 0.926   0.13 0.13 0.206       Genotypic 
3 26792607 rs11914329 LRRC3B 0.19 0.14 0.99 1.31x10-8   0.15 0.15 0.779   0.13 0.14 0.451       Genotypic 
3 26794821 rs1488250 LRRC3B 0.17 0.13 1.00 5.28x10-7   0.14 0.14 0.940   0.14 0.14 0.461       Genotypic 
3 26796445 rs6768401 LRRC3B* 0.17 0.13 NA 2.00x10-7   0.14 0.14 0.922   0.13 0.14 0.490       Genotypic 
3 26798614 rs1032885 LRRC3B 0.18 0.14 1.00 1.25x10-8   0.15 0.15 0.848   0.13 0.14 0.210       Genotypic 
4 83324569 rs11099533   0.15 0.11 NA 6.86x10-8   NA NA NA   NA NA NA       Genotypic 
4 88413965 rs17012693 SPARCL1 0.33 0.21 0.95 2.06x10-7 
2.04 (1.56-
2.66) 0.21 0.24 0.787 
0.88 (0.35-
2.23) 0.21 0.21 0.936 0.98 (0.6-1.6) 1.14x10-5 
1.66 (1.32-
2.08) Additive 
7 35394619 rs138302119 0.16 0.11 NA 4.47x10-7   NA NA NA   NA NA NA     
 
Genotypic 
8 73087935 rs1809447   0.16 0.11 0.99 6.61x10-7   0.15 0.10 0.328   0.06 0.07 0.733       Genotypic 
8 134298504 rs16904882 NDRG1 0.20 0.11 0.95 1.08x10-8 
2.78 (1.95-
3.94) 0.00 0.11 0.988 NA 0.14 0.11 0.295 
1.28 (0.81-
2.01) 1.96x10-7 
2.08 (1.58-
2.74) Additive 
8 139215155 rs11985359 FAM135B 0.16 0.19 0.99 5.05x10-7   0.19 0.22 0.580   0.18 0.18 0.527       Genotypic 
10 121497290 rs73355807 INPP5F 0.21 0.15 0.99 6.40x10-7   0.17 0.14 0.630   0.08 0.11 0.246       Genotypic 
12 125614614 rs76336213 AACS 0.19 0.11 0.93 6.65x10-7 
2.56 (1.77-
3.70) 0.15 0.12 0.395 
1.34 (0.68-
2.63) 0.09 0.08 0.632 
1.14 (0.67-
1.93) 5.44x10-5 
1.80 (1.35-
2.39) Additive 
13 69576658 rs73211791   0.15 0.11 0.99 2.56x10-7   0.11 0.12 0.972   0.11 0.15 0.137       Genotypic 
13 69582740 rs9541709   0.16 0.12 0.99 3.78x10-9   0.11 0.12 0.993   0.18 0.17 0.956       Genotypic 
19 7900650 rs652710 EVI5L 0.24 0.37 0.94 1.21x10-6 
0.56 (0.45-
0.71) 0.40 0.36 0.550 1.17 (0.7-1.95) 0.33 0.36 0.474 
0.89 (0.66-
1.21) 1.60x10-4 
0.71 (0.60-
0.85) Additive 
19 7903484 rs604938 EVI5L** 0.34 0.46 0.99 2.17x10-5 
0.62 (0.50-
0.78) 0.46 0.45 0.416 1.19 (0.75-1.9) 0.44 0.42 0.589 
1.08 (0.81-
1.44) 0.016 
0.81 (0.69-
0.96) Additive 
19 7910854 rs794442 EVI5L** 0.33 0.45 0.99 1.27x10-5 
0.62 (0.50-
0.77) 0.67 0.45 0.629 
1.11 (0.69-
1.76) 0.42 0.41 0.754 
1.05 (0.79-
1.39) 4.27x10-3 
0.79 (0.67-
0.93) Additive 
19 7916620 rs580790 EVI5L 0.22 0.36 0.87 1.33x10-7 
0.53 (0.42-
0.67) 0.40 0.31 0.110 
1.51 (0.91-
2.49) 0.30 0.34 0.382 
0.88 (0.65-
1.18) 1.23x10-4 
0.71 (0.6-
0.85) Additive 
19 7922672 rs2059820 EVI5L 0.22 0.36 0.87 1.35x10-7 
0.53 (0.42-
0.67) 0.42 0.32 0.356 
1.39 (0.69-
2.81) 0.29 0.31 0.529 0.9 (0.64-1.26) 1.72x10-5 
0.67 (0.55-
0.80) Additive 
21 35289246 rs2834301 ATP5O* 0.24 0.15 NA 8.59x10-7   0.10 0.17 0.202   0.17 0.13 0.366       Genotypic 
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highlighted**), these data are presented. rs13390936 (highlighted in bold) was genotyped by High-Resolution Melt-curve Analysis 
(HRMA). Sample numbers are as indicated in the table, with the exception of Immunochip genotyped SNPs (Kenyan replication, 38 
cases, 1,336 controls) and rs13390936 (Kenyan replication, 38 cases, 1,336 controls; Malawian replication, 150 cases, 339 controls). 
Imputation accuracy (proportion of correctly imputed genotypes) is calculated for a subset of Sequenom genotyped Kenyan discovery 
samples (180 cases, 750 controls), SNPs directly genotyped in the discovery analysis are highlighted (*). Odds ratios are given for 
SNPs associated with NTS disease in the Kenyan discovery samples under an additive model. For SNPs associated with disease under 
a genotypic model odds ratios are not reported.  CHR, chromosome; BP (b37), base-pair position Human Genome Reference 
GRCh37; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.
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Genetic model 
Population 
Genotypic Additive Recessive Dominant 
Heterozygous 
advantage 
P AIC P AIC P AIC P AIC P AIC 
Kenya (discovery) 1.76x10-5 1351 0.012 1359 3.33x10-6 1349 0.141 1363 0.782 1365 
Kenya (replication) 1.83x10-3 340 0.398 346 6.54x10-4 339 0.869 347 0.209 345 
Malawi 0.039 586 0.559 589 0.026 584 0.917 589 0.379 589 
Supplementary Table 5 | Genetic model comparison of rs13390936 association with NTS. 
Comparison of the observed rs13390936 association with NTS bacteraemia under alternative 
genetic models. AIC, Akaike information criterion. 
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  Kenya discovery (imputed) Kenya replication Malawi replication Combined analysis* 
SNP 
Position 
(chr:bp) 
r2 to 
rs13390936 OR (95% CI) P 
Imputation 
accuracy 
OR (95% 
CI) P OR (95% CI) P 
OR (95% 
CI) P 
rs13390936 2:191954816 1 
6.59 (2.68-
14.78)** 1.74x10-8 0.97 
9.96 (2.66-
37.36) 6.54x10-4 4.89 (1.21-19.83) 0.026 
6.81 (3.67-
12.63)** 1.21x10-9 
rs16833239 2:191940260 0.97 
5.87 (2.54-
12.43) 8.07x10-7 0.95 
9.14 (2.47-
33.86) 9.24x10-4 5.41 (1.04-28.24) 0.045 
6.38 (3.48-
11.70) 1.99x10-9 
rs13401064 2:191970330 0.96 
5.41 (2.24-
11.80) 4.10x10-7 0.97 
7.51 (2.06-
27.39) 2.24x10-3 1.73 (0.46-6.54) 0.421 
4.61 (2.54-
8.37) 5.20x10-7 
rs12693593 2:191964323 0.96 
5.41 (2.24-
11.80) 4.37x10-7               
rs13407419 2:191968420 0.96 
5.41 (2.24-
11.80) 4.48x10-7 0.97 
6.15 (1.72-
21.90) 5.10x10-3 8.59 (0.95-77.57) 0.056 
5.81 (3.07-
10.97) 5.98x10-8 
rs9789710 2:191957413 0.93 
5.51 (2.51-
11.18) 2.99x10-8               
rs143464908 2:191955597 0.92 
7.90 (2.94-
19.40) 4.62x10-8               
 
Supplementary Table 6 | NTS association (recessive model) at a set of SNPs in the STAT4 region with a 95% probability of containing the 
causal variant. rs16833239, rs13401064 and rs13407419 were genotyped using the Immunochip (Kenya replication samples) and Sequenom 
MASSArray assays (Malawi replication samples). rs16833239, rs13401064 and rs13407419  was also genotyped in 33% of the Kenyan discovery 
samples (n=938) using Sequenom MASSArray to confirm imputation accuracy. rs13390936 was genotyped in Kenyan and Malawian replication 
samples using HRMA, and imputation accuracy confirmed in 100% of the Kenyan discovery samples. 
*Fixed effects meta-analysis of Kenyan discovery (imputed), Kenyan replication (directly genotyped) and Malawian replication (directly genotyped) 
populations. OR, odds ratio; CI, confidence interval. 
**Discrepancies between p-values and effect sizes displayed for Kenyan discovery samples displayed here, and those reported in Table 1, reflect the 
use of imputed genotypes (here) and directly assayed genotypes (Table1). 
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Kenya discovery 
(n=180) 
Kenya replication 
(n=38) 
Kenya total 
(n=218) 
Malawi replication 
(n=150) P 
 
Age (months) 15 (0-143) 14 (0-52) 15 (0-143) 16 (0-180) 0.050 
 
Female 85/180 (47.2%) 19/38 (50.0%) 104/218 (47.7%) 68/150 (45.3%) 0.732 
N
TS
 
se
ro
va
r Typhimurium 66/166 (39.8%) 12/33 (36.4%) 78/199 (39.2%) 135/150 (90.0%) <0.0001 
Enteritidis 84/166 (50.6%) 20/33 (60.6%) 104/199 (52.3%) 12/150 (8.0%) <0.0001 
Not typable* 16/166 (9.6%) 1/33 (3.0%) 17/199 (8.5%) 3/150 (2.0%) 0.018 
Co
-
m
or
bi
di
tie
s HIV-infection 24/117 (20.5%) 6/30 (20.0%) 30/147 (20.4%) 49/126 (38.9%) 0.001 
Malaria 55/179 (30.7%) 15/38 (39.5%) 70/217 (32.3%) 26/143 (18.2%) 0.005 
Severe 
wasting** 62/160 (38.8%) 10/32 (31.3%) 72/192 (37.5%) 48/133 (36.1%) 0.887 
 
Mortality 38/178 (21.3%) 10/36 (27.8%) 48/214 (22.4%) 17/150 (11.3%) 0.01 
Supplementary Table 7 | NTS serovars & co-morbidities in Kenyan & Malawian case samples. 
Distribution of NTS serovars and common NTS-associated co-morbidities in the Kenyan discovery, Kenyan 
replication and Malawian replication NTS cases. P-values represent comparisons of age (linear regression), or 
the proportions of a given clinical characteristic (χ2 test), between study populations (Kenya total vs. Malawi 
replication). 
*with available antisera. 
**Severe wasting defined as weight-for-age z-scores <-3. 
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rs13390936 genotype 
 
 
Total (n=106) AA (n=77) AT (n=25) TT (n=4) P 
Demographics           
Age, months (median, IQR) 16, 8-31 16, 8-33 14, 11-21 23, 11-49 0.4 
Female (no., prop.) 50/106, 0.47 36/77, 0.47 12/25, 0.48 2/4, 0.5 0.88 
Co-morbidity           
Malaria (no., prop.) 6/103, 0.06 3/75, 0.04 3/24, 0.13 0/4, 0 0.38 
HIV (no., prop.) 43/104, 0.41 32/76, 0.42 10/24, 0.42 1/4, 0.25 0.65 
Severe malnutrition (no., prop.) 24/98, 0.24 17/69, 0.25 6/25, 0.24 1/4, 0.25 0.97 
Clinical features at admission           
Febrile (no., prop.) 83/99, 0.78 61/74, 0.82 20/22, 0.91 2/3, 0.67 0.78 
Tachycardia* (no., prop.) 19/31, 0.61 16/26, 0.62 3/5, 0.6 ND 1 
Tachypnoea* (no., prop.) 24/35, 0.69 18/28, 0.64 6/7, 0.86 ND 0.52 
Respiratory distress** (no., prop.) 29/78, 0.37 19/54, 0.35 10/20, 0.5 0/4, 0 0.87 
BCS<5 (no., prop.) 9/99, 0.09 8/72, 0.11 0/22, 0 1/4, 0.25 0.64 
Outcome           
In-patient mortality (no., prop.) 14/106, 0.13 9/77, 0.12 5/25, 0.2 0/4, 0 0.73 
 
Supplementary Table 8 | Demographics and clinical characteristics of Malawian NTS cases included in 
serum IFNγ experiment. Data is presented for the Malawian NTS cases (n = 106), for whom serum IFNγ 
levels during acute disease were correlated with genotype at rs13390936. P-values represent correlation of age 
(linear regression), or the proportions with a given clinical feature (χ2 test for trend), with genotype at 
rs13390936. No, number; prop, proportion; ND, no data. *rates > 90th centile for age. **presence of any of 
intercostal/subcostal recession, nasal flare, tracheal tug, head bobbing. 
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Kenya discovery Kenya replication Malawi replication 
   
Cases Controls Cases Controls Cases Controls 
  
Numbers* 180 2,677 38 1,336 150 339 
  
Median age in 
months (range) 15 (0-143) BC 14 (0-52) BC 16 (0-180) 18 (0-182) 
  
Females 47.2% 49.6% 50.0% 49.5% 45.3% 49.6% 
Re
po
rt
ed
 e
th
ni
ci
ty
 
Ke
ny
a Giriama 50.0% 45.8% 33.3% 40.0%     
Chonyi 30.4% 37.1% 41.6% 44.1%     
Kauma 7.6% 11.9% 8.3% 10.3%     
M
al
aw
i Chewa         20.7% 11.8% 
Yao         14.0% 19.2% 
Lomwe         28.7% 28.6% 
Ngoni         16.7% 24.8% 
Supplementary Table 9 | NTS bacteraemia genetic association study sample demographics. Demographic 
data for cases and controls in Kenyan discovery, Kenyan replication and Malawian replication samples sets. 
*Numbers included in final analysis. BC, birth cohort. 
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